Commentary|Videos|November 18, 2026

PARADIGM Supports Venetoclax/Azacitidine in Select Fit AML Populations

Amir T. Fathi, MD, discusses where venetoclax/azacitidine fits in fit patients with AML and why a phase 3 trial may be unlikely.

In the randomized phase 2 PARADIGM trial (NCT04801797) of 172 previously untreated adults with acute myeloid leukemia (AML) who were candidates for induction chemotherapy, azacitidine (Vidaza) plus venetoclax (Venclexta) improved median event-free survival compared with intensive chemotherapy (14.5 vs 6.2 months; HR, 0.57; 95% CI, 0.39-0.84; P = .002).Median overall survival (OS) was 21.5 vs 18.0 months, although the trial was not designed to formally assess OS differences, and patients with core binding factor fusions, FLT3 mutations, and NPM1 mutations younger than 60 years were excluded.1

Amir T. Fathi, MD, director of the leukemia program at the Mass General Brigham Cancer Institute and professor of medicine at Harvard Medical School, spoke with CancerNetwork® at the 44th Annual Chemotherapy Foundation Symposium (CFS®), hosted by Physicians’ Education Resource®, LLC, following his presentation, “Challenging the Dogma in Frontline AML Management.” He highlighted whether venetoclax/azacitidine has a role in fit patients and what data would be needed before moving away from 7+3 therapy.

Transcript:

CancerNetwork: Venetoclax/azacitidine has become the backbone for patients who aren’t fit for intensive chemotherapy. Is there a role for it in fit patients, and what data would you want to see before moving away from 7+3?

Fathi: We published the randomized phase 2 PARADIGM study, which I think supports the use of hypomethylating agents and venetoclax in some fit patients with acute myeloid leukemia.1 Again, we did not include some of the subtypes, such as FLT3-mutated, core binding factor, and younger NPM1-mutated [populations]; those will need their own dedicated studies. But for the other patients, I think the current data support the use of hypomethylating agents such as azacitidine and venetoclax, even if patients are fit. I do think the field is moving in that direction.

A dedicated phase 3 registrational approach is likely to be difficult because it requires a large trial, often with the involvement of industry, and I’m not sure industry is interested in engaging in a very large study comparing these 2 [approaches] for upfront AML.

Reference

Fathi AT, Perl AE, Fell GG, et al. Azacitidine–venetoclax or induction chemotherapy for acute myeloid leukemia. N Engl J Med. 2026;395(9):845-858. doi:10.1056/NEJMoa2602804


Related to this article